$657 Million is the total value of COMMODORE CAPITAL LP's 32 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 26.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XENE | Buy | XENON PHARMACEUTICALS INC | $66,032,550 | +100837.9% | 1,845,000 | +11.2% | 10.05% | +2.0% |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $55,704,925 | +94300.7% | 2,189,659 | +8.4% | 8.48% | -4.6% |
| MRUS | Buy | MERUS N V | $54,280,000 | +128303.5% | 2,950,000 | +8.0% | 8.26% | +29.7% |
| COGT | Buy | COGENT BIOSCIENCES INC | $51,494,423 | +103014.6% | 4,772,421 | +10.5% | 7.84% | +4.2% |
| BLU | Buy | BELLUS HEALTH INC NEW | $47,371,385 | +108562.4% | 6,579,359 | +24.1% | 7.21% | +9.8% |
| AMAM | New | AMBRX BIOPHARMA INCsponsored ads | $42,846,747 | – | 4,803,447 | +100.0% | 6.52% | – |
| New | ENLIVEN THERAPEUTICS INC | $37,916,894 | – | 1,731,365 | +100.0% | 5.77% | – | |
| AKRO | Buy | AKERO THERAPEUTICS INC | $30,225,400 | +102595.7% | 790,000 | +47.1% | 4.60% | +3.7% |
| Buy | NUVALENT INC | $28,046,750 | +102982.7% | 1,075,000 | +17.7% | 4.27% | +4.1% | |
| IMVT | Buy | IMMUNOVANT INC | $22,349,894 | +109345.6% | 1,440,999 | +25.2% | 3.40% | +10.6% |
| VERA | New | VERA THERAPEUTICS INCcl a | $21,914,465 | – | 2,824,029 | +100.0% | 3.34% | – |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $18,034,030 | +102828.1% | 853,884 | +24.0% | 2.75% | +4.0% |
| CABA | Buy | CABALETTA BIO INC | $15,175,450 | +162273.7% | 1,835,000 | +81.6% | 2.31% | +64.1% |
| KURA | Buy | KURA ONCOLOGY INC | $14,736,636 | +107908.2% | 1,204,958 | +9.6% | 2.24% | +9.1% |
| ARWR | Buy | ARROWHEAD PHARMACEUTICALS IN | $14,605,000 | +77822.4% | 575,000 | +24.4% | 2.22% | -21.3% |
| CELC | Buy | CELCUITY INC | $14,255,413 | +76521.4% | 1,390,772 | +4.7% | 2.17% | -22.6% |
| ALLK | Buy | ALLAKOS INC | $8,455,000 | +60999.9% | 1,900,000 | +15.6% | 1.29% | -38.3% |
| PCVX | Buy | VAXCYTE INC | $7,496,000 | +90017.8% | 200,000 | +15.3% | 1.14% | -9.0% |
| ADVM | New | ADVERUM BIOTECHNOLOGIES INC | $3,587,000 | – | 5,000,000 | +100.0% | 0.55% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 12 | Q3 2023 | 10.3% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.4% |
| VIRIDIAN THERAPEUTICS INC | 11 | Q3 2023 | 8.9% |
| CYMABAY THERAPEUTICS INC | 11 | Q2 2023 | 5.4% |
| KURA ONCOLOGY INC | 11 | Q3 2023 | 7.1% |
| CELLDEX THERAPEUTICS INC NEW | 11 | Q3 2023 | 3.8% |
| ACLARIS THERAPEUTICS INC | 10 | Q1 2023 | 10.4% |
| CELCUITY INC | 10 | Q3 2023 | 7.3% |
| KALVISTA PHARMACEUTICALS INC | 10 | Q2 2023 | 2.2% |
| MERUS N V | 9 | Q3 2023 | 12.5% |
View COMMODORE CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | April 27, 2023 | 31,181,983 | 8.1% |
| BELLUS Health Inc. | March 30, 2023 | 6,579,359 | 5.2% |
| IMARA Inc. | February 21, 2023 | 2,840,754 | 10.8% |
| Karyopharm Therapeutics Inc. | February 14, 2023 | 1,935,609 | 1.7% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Satsuma Pharmaceuticals, Inc.Sold out | November 16, 2022 | 0 | 0.0% |
| GENOCEA BIOSCIENCES, INC. | February 14, 2022 | 3,079,756 | 5.4% |
View COMMODORE CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| SC 13G | 2024-03-21 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View COMMODORE CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.